U.S. Capital Wealth Advisors LLC Has $619,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

U.S. Capital Wealth Advisors LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 90.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,705 shares of the biopharmaceutical company's stock after selling 64,693 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Gilead Sciences were worth $619,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in GILD. Greenleaf Trust lifted its position in Gilead Sciences by 5.4% during the 4th quarter. Greenleaf Trust now owns 26,548 shares of the biopharmaceutical company's stock valued at $2,452,000 after purchasing an additional 1,351 shares during the period. Spire Wealth Management raised its stake in shares of Gilead Sciences by 9.1% during the fourth quarter. Spire Wealth Management now owns 15,560 shares of the biopharmaceutical company's stock worth $1,437,000 after buying an additional 1,295 shares during the last quarter. Journey Strategic Wealth LLC boosted its position in shares of Gilead Sciences by 5.1% in the 4th quarter. Journey Strategic Wealth LLC now owns 5,913 shares of the biopharmaceutical company's stock worth $546,000 after purchasing an additional 288 shares during the last quarter. Tritonpoint Wealth LLC increased its holdings in Gilead Sciences by 6.5% in the fourth quarter. Tritonpoint Wealth LLC now owns 6,266 shares of the biopharmaceutical company's stock valued at $579,000 after purchasing an additional 381 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its stake in Gilead Sciences by 5.4% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 37,354 shares of the biopharmaceutical company's stock valued at $3,450,000 after buying an additional 1,915 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GILD shares. Wells Fargo & Company upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. UBS Group lifted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Truist Financial upped their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research report on Friday, November 8th. Finally, Maxim Group lowered Gilead Sciences from a "buy" rating to a "hold" rating in a report on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.39.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock valued at $53,611,715 in the last three months. Insiders own 0.16% of the company's stock.

Gilead Sciences Trading Down 2.0 %

NASDAQ GILD traded down $2.00 during trading hours on Friday, reaching $96.04. The company's stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The firm has a fifty day simple moving average of $93.04 and a 200-day simple moving average of $86.76. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51. The stock has a market cap of $119.69 billion, a P/E ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.29 earnings per share. Equities analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.